Brief: Invion Expands Agreement With Hanlim To Include Oesophageal Cancer
26/02/2025 01:16
Feb 26 (Reuters) - Invion Ltd IVX.AX: EXPANDED COLLABORATION & FUNDING AGREEMENT WITH MAJOR SOUTH KOREAN PHARMACEUTICAL GROUP HANLIM TO INCLUDE OESOPHAGEAL CANCER Further company coverage: IVX.AX ((Reuters.Briefs@thomsonreuters.com))
Recent news on Invion
See all newsAustralia's Invion rises after securing clinical trial funding arrangements
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation